As the US FDA weighs implementation of a suffix-based naming system for biologics, the World Health Organization has decided to shelve, at least for now, its own plan for a different naming convention.
Nine months after issuing a final guidance on nonproprietary naming of biological products, FDA has yet to approve a 351(a)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?